CY
CYP.AU Cynata Therapeutics Ltd
- Market cap
- AUD 2.92M
- P/E
- -
- P/B
- 0.75x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CYP.AU undervalued?
Graham numberThe Graham number of Cynata Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cynata Therapeutics Ltd fundamental analysis
5 of 21 checks passedROE 0/2
ROE cannot be calculated: equity is negative or not reported.
ROA 0/1
Return on assets (-682.8%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (14.7%) is above the industry median (-5.3%).
Revenue Growth 1/2
Revenue grew 1.1% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.8x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Cynata Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for …
Full company profileCynata Therapeutics Ltd financial statements
Cynata Therapeutics Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.75M | 1.38M | 1.31M | 7.01M | 1.55M | 7.77M | 1.65M | 2.32M | 1.89M | 1.71M |
| Gross Profit | 1.47M | 1.10M | 1.03M | 6.73M | 1.27M | 7.49M | 1.37M | 2.32M | 1.89M | -260K |
| Operating Income | -6.33M | -6.13M | -10.1M | -10.5M | -9.08M | -6.90M | -16.5M | -8.81M | -8.12M | -9.68M |
| EBITDA | -6.02M | -5.61M | -9.50M | -5.87M | -8.80M | -6.00M | -15.7M | -9.95M | -9.33M | -9.42M |
| Net Income | -4.55M | -4.57M | -8.47M | -3.64M | -7.69M | -5.45M | -14.3M | -9.74M | -9.39M | -9.25M |
| EPS | -0.06 | -0.05 | -0.08 | -0.03 | -0.06 | -0.04 | -0.10 | -0.05 | -0.05 | -0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 14.3M | 16.1M | 12.2M | 17.5M | 30.0M | 26.5M | 19.0M | 8.39M | 7.20M | 1.35M |
| Total Liabilities | 390K | 746K | 1.28M | 690K | 1.60M | 2.59M | 2.26M | 1.17M | 1.22M | 1.75M |
| Shareholders' Equity | 13.9M | 15.4M | 11.0M | 16.8M | 28.4M | 24.0M | 16.7M | 7.22M | 5.98M | -394K |
| Cash & Short-term Investments | 10.3M | 12.2M | 6.98M | 13.6M | 26.7M | 23.8M | 16.2M | 6.21M | 5.05M | 897K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.05M | -4.06M | -6.76M | -3.39M | -5.16M | -3.30M | -14.3M | -9.96M | -8.72M | -6.74M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 50.0K | 0.00 |
| Free Cash Flow | -4.05M | -4.06M | -6.76M | -3.39M | -5.16M | -3.30M | -14.3M | -9.96M | -8.77M | -6.74M |
| Ratios | ||||||||||
| ROE | -32.8% | -29.7% | -77.2% | -21.7% | -27.1% | -22.7% | -85.3% | -135.0% | -157.0% | - |
| ROA | -31.9% | -28.3% | -69.2% | -20.8% | -25.7% | -20.5% | -75.2% | -116.2% | -130.5% | -682.8% |
| Net Profit Margin | -260.4% | -332.0% | -647.4% | -51.9% | -497.4% | -70.1% | -863.0% | -420.8% | -498.1% | -540.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cynata Therapeutics Ltd dividends
Cynata Therapeutics Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 1:20 on Oct 31, 2013.
Who owns Cynata Therapeutics Ltd
- Insiders 24.97%
- Institutions 7.88%
- Public & others 67.15%
- Shares outstanding 243M
- Free float 210M
Cynata Therapeutics Ltd company profile
- Company name
- Cynata Therapeutics Ltd
- Ticker
- CYP.AU
- ISIN
- AU000000CYP7
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 100 Cubitt Street, Cremorne, VIC, Australia, 3121
- Phone
- 61 3 7067 6940
- Website
- cynata.com
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for intravenous use that is in a Phase 1/2 clinical trial for NEREID kidney transplantation; and CYP-006TK, an iPSC-derived MSC topical wound dressing product candidate that completed a Phase 1 trial for the treatment of diabetic foot ulcer. It is also developing pre-clinical pipeline products for asthma, cancer, cardiovascular, sepsis, critical limb ischemia, and idiopathic pulmonary fibrosis indications. The company has a strategic partnership agreement with FUJIFILM Corporation, as well as partnerships with the University of Sydney and Leiden University Medical Center. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Cynata Therapeutics Ltd management
1- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary · born 1963